ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1642137
Efficacy and Safety of Telitacicept in the Treatment of IgA Nephropathy: A Single-Center, Real-World Study
Provisionally accepted
- Henan Provincial People's Hospital, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aim: To evaluate the efficacy and safety of Telitacicept in patients with IgA nephropathy. Telitacicept is a fusion protein that inhibits B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby modulating B-cell activation and survival. Methods: A single-center, retrospective analysis of data from 24 patients with IgA nephropathy who received telitacicept 160 mg per week, with a minimum continuous treatment of 12 weeks, from August 2022 to January 2024. Patients were categorized by treatment regimen: telitacicept monotherapy (Group A, n=8), telitacicept combined with low-dose corticosteroids (prednisone 0.3–0.5 mg/kg/day) (Group B, n=8), and telitacicept combined with full-dose corticosteroids or corticosteroids plus other immunosuppressants (Group C, n=8). Clinical data before treatment (baseline) and after 4, 12, and 24 weeks of treatment were analyzed and safety assessed. Results: Mean serum creatinine and eGFR levels remained stable in all three groups. After 12 weeks and 24 weeks of treatment, patients in all three groups showed a significant decrease in 24 hour proteinuria from baseline (P<0.05). Treatment with Telitacicept was generally well-tolerated, with no serious adverse events related to the study drug. Complete remission was achieved in 4 patients (16.7%), partial remission in 15 patients (62.5%), and no response in 5 patients (20.8%). Conclusions: Telitacicept monotherapy is safe and effective, and combination with corticosteroids and immunosuppressants may improve the remission rate in patients with better baseline renal function, but modestly increases the risk of adverse reactions.
Keywords: Telitacicept, IgA nephropathy, Proteinuria, Immunoglobulins, EGFR
Received: 06 Jun 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Tao, Zhang, Niu, Liu, Xiaojing, Shao and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huixia Cao, Henan Provincial People's Hospital, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.